Fermer le menu

Member of Lyonbiopole


GAOMA Therapeutics is an early-stage biotech based in France, with an expertise in the development of bioactive lipids derivatives.

The company’s first asset, GAO-3-02, is a first-in-class small molecule in pre-clinical development for the treatment of epilepsy with a very novel mechanism of action which can improve the cognitive deficit and inhibit the neuroinflammation associated with this indication.


Strategic application domain: Human Medicine

Application market: Neurology & Mental Health Disorders, Pain, Pediatrics

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Small Molecules

Created on feb. 26th, 2019 - 2 employees



Institut Des Epilepsies Europe - IDEE, 59 Boulevard Pinel 69500 Bron



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.